PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07K 16/40, C12N 5/06, A61K 47/48, G01N 33/573, 33/574, 33/577, A61P 35/00, C12N 9/02

A1

(11) International Publication Number: WO 00/56773

(43) International Publication Date: 28 September 2000 (28.09.00)

(21) International Application Number: PCT/GB00/01030

(22) International Filing Date: 20 March 2000 (20.03.00)

(30) Priority Data:
9906380.2 19 March 1999 (19.03.99) GB

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF ABERDEEN [GB/GB]; Research and Innovation, 23 St Machar Drive, Aberdeen AB24 3RY (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MELVIN, William [GB/GB]; 5 Deeside Park, Aberdeen AB15 7PQ (GB). MURRAY, Graeme, Ian [GB/GB]; 29 Woodhill Road, Aberdeen AB2 4JU (GB).

(74) Agents: KIDDLE, Simon, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: ANTIBODIES SPECIFIC FOR CYP1B1

(57) Abstract

Antibodies that can specially bind to cytochrome P450 CYP1B1 and methods of making them are disclosed, in particular antibodies that bind to amino acid sequence VNQWSVNHDPVKWPN or PExFDPARFLDKDGy, where x is D or N and y is L or F, or an antigenic fragment thereof. The antibodies can be used in the diagnosis or treatment of cancers linked to enhanced CYP1B1 expression, including breast cancer, prostate cancer, colorectal cancer, liver cancer and ovarian cancer.